14,883 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by MSH Capital Advisors LLC

MSH Capital Advisors LLC bought a new position in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 14,883 shares of the company’s stock, valued at approximately $2,152,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Wasatch Advisors LP grew its position in shares of Johnson & Johnson by 5.9% in the 4th quarter. Wasatch Advisors LP now owns 41,954 shares of the company’s stock worth $6,067,000 after buying an additional 2,338 shares during the last quarter. NewEdge Advisors LLC lifted its position in Johnson & Johnson by 5.2% during the 4th quarter. NewEdge Advisors LLC now owns 295,396 shares of the company’s stock worth $42,720,000 after acquiring an additional 14,659 shares during the period. Stenger Family Office LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $2,158,000. NFJ Investment Group LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $10,774,000. Finally, Finward Bancorp acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $1,554,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE JNJ opened at $153.66 on Wednesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The business has a fifty day simple moving average of $159.39 and a 200-day simple moving average of $155.10. The company has a market cap of $370.29 billion, a price-to-earnings ratio of 23.11, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Morgan Stanley increased their price target on shares of Johnson & Johnson from $163.00 to $164.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $171.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.